Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion is recommended as an option for use within NHS Wales for the treatment of HER2 positive early breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. |
|||
|
|||
Medicine details |
|||
| Medicine name | trastuzumab (Herceptin®) | ||
| Formulation | powder for concentrate for solution for infusion | ||
| Reference number | 1409 | ||
| Indication | Treatment of HER2 positive early breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter |
||
| Company | Roche Products Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 2812 | ||
| NMG meeting date | 10/07/2012 | ||
| AWMSG meeting date | 12/09/2012 | ||
| Ratification by Welsh Government | 25/10/2012 | ||
| Date of issue | 01/11/2012 | ||
| Date of last review | 30/08/2016 | ||